Holen Sie sich die Stockscreener-App
5.72
4.00%
0.22
Schlusskurs vom Vortag:
$5.50
Offen:
$5.67
24-Stunden-Volumen:
719.34K
Relative Volume:
0.63
Marktkapitalisierung:
$417.49M
Einnahmen:
$531.00K
Nettoeinkommen (Verlust:
$-104.97M
KGV:
-2.1172
EPS:
-2.7017
Netto-Cashflow:
$-107.19M
1W Leistung:
-0.61%
1M Leistung:
-16.98%
6M Leistung:
-12.00%
1J Leistung:
+28.83%
1-Tages-Spanne:
$5.67
$5.96
1-Wochen-Bereich:
$5.22
$5.96
52-Wochen-Spanne:
$1.45
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Firmenname
Lexeo Therapeutics Inc
Sektor
Branche
Telefon
(212) 547-9879
Adresse
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
5.72 | 401.43M | 531.00K | -104.97M | -107.19M | -2.7017 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Eingeleitet | Raymond James | Strong Buy |
| 2025-11-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-10-15 | Eingeleitet | Guggenheim | Buy |
| 2025-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-11-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-11-28 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-28 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-11-28 | Eingeleitet | Stifel | Buy |
Alle ansehen
Lexeo Therapeutics Inc Aktie (LXEO) Neueste Nachrichten
Wall Street Recap: Is Lexeo Therapeutics Inc. subject to activist investor interestTrade Risk Report & Precise Buy Zone Tips - baoquankhu1.vn
Hedge Fund Moves: Does Lexeo Therapeutics Inc have declining or rising EPSMarket Growth Report & Long-Term Safe Return Strategies - baoquankhu1.vn
Published on: 2026-03-22 00:04:32 - baoquankhu1.vn
Oppenheimer Initiates Coverage of Lexeo Therapeutics (LXEO) with Outperform Recommendation - MSN
Is Lexeo Therapeutics Inc forming a bullish divergence2026 EndofYear Setup & Daily Profit Focused Screening - baoquankhu1.vn
Lexeo Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
[Form 4] Lexeo Therapeutics, Inc. Insider Trading Activity - Stock Titan
Lexeo Therapeutics (LXEO) CEO acquires 2,623 shares via employee stock plan - Stock Titan
Signal Recap: Can Lexeo Therapeutics Inc ride the EV waveMarket Trend Summary & Proven Capital Preservation Methods - baoquankhu1.vn
Lexeo Therapeutics (LXEO) Projected to Post Earnings on Monday - MarketBeat
LEXEO THERAPEUTICS Q4 2025 Earnings Preview: Recent $LXEO Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
LXEO Stock Chart | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
Lexeo Therapeutics (NASDAQ:LXEO) Shares Up 10.4%What's Next? - MarketBeat
Sectors Review: Is Lexeo Therapeutics Inc. subject to activist investor interestWeekly Trade Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
Is Lexeo Therapeutics Inc a cyclical or defensive stockMarket Volume Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
Wall Street rallies behind Lexeo Therapeutics (LXEO)’s gene therapy pipeline - MSN
Published on: 2026-03-07 09:09:20 - baoquankhu1.vn
Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference - The Manila Times
Genetic medicine firm Lexeo to stream Leerink conference chat - Stock Titan
Nasdaq Moves: Can Lexeo Therapeutics Inc ride the EV waveRate Cut & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Lexeo Therapeutics Highlights FA and PKP2 Cardiac Gene Therapy Progress at Oppenheimer Conference - MarketBeat
Cantor Fitzgerald Remains a Buy on Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
LXEO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Earnings Update: Is Lexeo Therapeutics Inc forming a bullish divergenceProduct Launch & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Profit Review: Is Lexeo Therapeutics Inc forming a bullish divergenceShare Buyback & Risk Controlled Stock Alerts - baoquankhu1.vn
Narinder Pal Bhalla Net Worth (2026) - GuruFocus
Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells $64,903.74 in Stock - Defense World
Lexeo Therapeutics (NASDAQ:LXEO) COO Sells $19,302.40 in Stock - Defense World
Will Lexeo Therapeutics Inc. outperform its industry peersEarnings Risk Summary & Capital Efficient Trade Techniques - mfd.ru
Balyasny Asset Management L.P. Increases Stake in Lexeo Therapeu - GuruFocus
Top Brass at Biotech Player Quietly Cash Out in Latest Insider Move - TipRanks
Balyasny Asset Management L.P. Increases Stake in Lexeo Therapeutics Inc. - GuruFocus
Lexeo Therapeutics (LXEO) CEO sells 10,173 shares in tax-related trade - Stock Titan
LXEO (NASDAQ: LXEO) affiliate plans sale of 4,867 vested shares - Stock Titan
LXEO (NASDAQ: LXEO) Form 144 reports 3,861 shares tied to vesting - Stock Titan
LXEO Should I Buy - Intellectia AI
Citadel discloses 7.4% Lexeo Therapeutics (LXEO) ownership in 13G/A - Stock Titan
BioAgilytix Labs, Inc Receives FDA Breakthrough Device Designation for Anti-AAV Antibody Assay - The Courier-Journal
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2026-02-16 16:57:11 - baoquankhu1.vn
Is Lexeo Therapeutics Inc. still a buy after recent gainsJuly 2025 Earnings & Fast Entry Momentum Trade Alerts - mfd.ru
Lexeo Therapeutics Details FDA Path for LX2006, Highlights LVMI Gains at Guggenheim Biotech Summit - MarketBeat
A | Does Lexeo Therapeutics, Inc. have declining or rising EPSPortfolio Update Report & Weekly Watchlist of Top Performers - mfd.ru
Page not foundAirwhon - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Down 3.2%Time to Sell? - MarketBeat
Will Lexeo Therapeutics Inc. announce a stock splitJuly 2025 Spike Watch & Smart Allocation Stock Reports - mfd.ru
Volatility Watch: Is Lexeo Therapeutics Inc backed by strong institutional buyingPortfolio Return Report & Low Risk High Reward Ideas - baoquankhu1.vn
Lexeo Therapeutics Announces Head of Research Transition - The Globe and Mail
Lexeo Therapeutics (LXEO) CFO receives RSUs and 226,665-share stock option - Stock Titan
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February - 富途牛牛
Finanzdaten der Lexeo Therapeutics Inc-Aktie (LXEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):